Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended

Filer: International Flavors & Fragrances Inc.

Subject Company: International Flavors & Fragrances Inc.

Filer's Commission File Number: 1-4858

Date: February 18, 2020

Global Town Hall

Event ID 2185371

Speaker: So good morning, good afternoon and good evening to everybody. We have planned a series of town hall meetings regarding our transaction with DuPont. And what we want to do today is we want to give you an overview why we believe it's a good move. We want to explain to you what kind of business is it and what the benefit for us as IF will provide this transaction. But now let me talk about the transaction with DuPont. Let's start with the first slide. I want to give you an overview about the business. I want to give you a clear idea about the strategic rationale behind the deal and the combination and then where are we in the integration and when do we really start and then give you the conclusion.

First of all, before we start with N&B DuPont business and overview where IFF is a standalone company because a lot has changed over the last two years as well within IFF. You can see here that we are playing since the acquisition of Frutarom, not just any longer on flavors, fragrances and ingredients, we are in savory solutions, natural colors, natural food protection and healthy ingredients business. You can read all of these numbers. The business has grown to a 5 billion plus business. You will see the final numbers actually during the earnings call week after next week for 2019. And you will appreciate what we have done over the last couple of quarters. Going into the history, I believe it's really important to understand for all of us that we had planned for move like this for quite some time. If you go to 2015 back, we have started with our first strategy. You can see here what the size of the company was and where we were playing. And then with Frutarom, we made actually an important next step. We did the acquisition in 2018. We have grown the business quite significantly and we are playing now in many more categories than we had played before. Now N&B gives us the next opportunity to solidify our business as a company and to change the market where we are playing in. I just want to pick a couple of numbers here. If you look at the R&D spend of the combined company, it's more than 500 million in R &D spend and I believe that will take us apart from everybody else who is playing in that room because that gives us the opportunity really to design the best and most innovative solutions for our customers going forward.

And also if you take the granted patents as a surrogate parameter for innovation, then you see that we will have more than 9,000 patents and that shows a lot of innovation and a lot of, let's say, technical platforms we have access to. Actually, it's even more because if you take on top of it the patents we have filed but which are not granted is around about 12,000. You see where we came from in 2015 and that basically shows the strengths of this combined company. By the way, I have received a lot of feedback from our customers. I just came back from the ACI Congress, the American Cleaning Institute in Orlando. We had, as we can on legal terms, discussions with our customers. They were congratulating us for the announcement of the transaction. And they are very, very excited because now the combined company is becoming, for many of them, the preferred provider and the preferred supplier for technology. They are very excited in particular for biotech solutions because we have now really access to first class biotech capabilities as a facility in Palo Alto which has around about 250 to 300 people just focusing on biotech, which will help us on the ingredient side a lot because, you know, and you remember in particular in the fragrance business, we had this supply crisis a year and a half, two years ago. And we believe that we can solve with these capabilities going forward much better than we've done in the past. So let's talk about the business. I don't want to read all the numbers. You can read it, but what is important, it's in

food and beverage, it's dietary supplements, animal nutrition, but also in home and personal care and pharmaexcipients.

The home and personal care here particular in this room where we have many people from the scent business is super complementary to what we are doing, particularly on the consumer fragrance business because they are providing a lot of enzymes, for example, for cleaning solutions, not just for some customers but for many of the major customers. And that will give us and I come to that in a moment, really a nice platform and none of our competitors right now can provide exactly the same for their customers. And I give it to you in actually two slides. The combined company will look like this in terms of size. What is really amazing is in all the categories we are playing, we will be a number one or number two position. I believe that this is really important. We have the broadest and largest customer base in the industry. Both companies are very committed to sustainability. That's something which is super important I think for all of us, but for many of our customers as well to do business with them. And we certainly have a very world class supply chain in place as well. But let me go a little bit more in detail. Let's start with R&D because R&D is always very close to my heart. Look at the numbers and the platforms here what we have now in store We have more than 50 R&D and creative centers with the combined company, which is really fantastic. We have more than 3000 scientists and engineers working on solutions from next year, hopefully after closing onwards. We have more than 40 university partnerships, which is really fantastic and about 12000 patents I talked already.

We believe that this will set us big times apart from everybody else in terms of our capabilities and in terms of way we can interact with our customers and come up with new solutions. So this is certainly a core piece of the idea behind the transaction. Yeah, I know it's tough to read, but just look at the different categories we are playing in, in the future. And if you combine the IFF and DuPont and N&B capabilities, we are playing in most of these areas in a number one or number two market position. And we believe this is super important as well, because you want to have a solid footprint with your customers in the areas where you're playing and you see as well when you have peer one to peer six that none of our bigger competitors can compete in terms of the wide array of different categories we are playing. And that gives us a lot of good access as well. I don't want to mention the probiotics and particularly in a season where it is wintery and everybody gets a little bit of a cold. I can already recommend, and hopefully let me do this, but probiotics are very healthy [inaudible] and in general very important to fight off many of these winter diseases. What was an interesting attraction for DuPont is that we have, with our tastepoint model on our taste side taking care of in particular smaller and midsized customers, a very nice platform which gives us good, let's say, access to these customers and they don't -- they play more with the bigger ones. So we believe that this creates a nice growth opportunity for us going forward as well, and will help us certainly in terms of integrated solutions because many of our customers, whether smaller or bigger, customers are asking us right now for integrated solutions. And I come exactly to this right now.

We have two examples, one on the taste side and one on the scent side. You can see here what is certainly on many people's mind is a plant based proteins. So how can you, let's say, have a burger patty with soy proteins or other protein sources, plant based protein sources. For us, you know, Beyond Meat, this is an important play in that space. And you can see

basically here what we as a company can deliver as a combined company to these. We basically can do the whole product and that gives us an excellent opportunities for many of these companies to create the whole thing and then sell it basically to, to these companies, because if you look at many of the startup companies, they don't have a lot of R&D capabilities or even manufacturing capabilities. And that's something which sets us apart from everybody else because they can give maybe the flavor or the seasoning or the natural antioxidants, but they can't do the plant based protein or emulsifier. But right now we have it all and we can deliver it all. And that's the beauty of the combination of these two businesses. Now going more into the scent side, which is pretty cool in particular for -actually both for fine fragrances but for consumer fragrances as well. Look at the laundry detergent. I don't want to read it, but if you are in the enzyme development already, then you can, let's say, foresee what's your customer already -- what is needed because I start with the enzyme actually earlier than with the fragrance. And we can look how the metrics and the interaction between the different compounds works as well.

What is really super important and that goes also to fine fragrance and I know we have many fine fragrance people here is we have now a really robust ingredient pipeline in particular biotech and we have, as IFF, tried so many times with third party manufacturers and outsourced R&D to get better biotech capabilities in, I think we were -- our success was limited, to be polite. Now we really have a good opportunity and a great platform to get exactly this in. So getting new molecules, new molecule discovery, green chemistry and biotech altogether, that will set us apart again because in that very field, none of our competitors has exactly that capability. And I believe these are just three examples. We will see more. I will travel with Nicolas for example, to Palo Alto in the next couple of weeks. We will look what we can do in terms of biotech to assess what are the real opportunities. And in all honesty, we started with the thinking in the strategy more from the taste point of view, but now we are discovering more and more what could happen on the scent business as well. And we believe this is super exciting for us. Integration team, you've seen it. Rich is leading it from IFF side. We have Angela on N&B side. I think it's a super cool combination. You mebody who comes from finance. You have somebody coming from R&D and they all have so have to figure it out. It will be very interesting, but I think they work very well together and we believe that the teams have now already made considerable progress to form all the sub teams and I come to that in a moment and establish a good IMO where we can work and establish a really, really strong relationship.

So in summary, we believe and then we will come up with, let's say, a new purpose for the combined company and a new vision as well, which will be certainly much far [inaudible] from what we have done so far. We will be certainly one of the most important ingredients and solutions providers. We will have a proven and trusted partner here. We go very deep into the end markets as well because we can in many instances we can do the whole thing, the whole solution. It's all science-led that something which comes very close to our heart. And I can tell you during the due diligence, I moved or walked into a couple of their facilities and it's basically the same language. It's the same dedication to science. And this is the same professionalism as you find in IFF. And that's something which hopefully makes it easier for us. Our product portfolio, I talked about, it's just amazing and it's very much on sustainability focused company as well. And you all know that sustainability is very close to my heart, but very close to the heart of our customers as well. So all in all, we believe it will

Global Town Hall

5

be a fantastic combination and it will take us probably around 12 months to close the deal. Until then, we are still two separate companies. That's how we operate, but we already can start to plan to come together and I hope next year, this time when we stand that we are already a combined company that we already have at the ACI Congress in Orlando, a combined booth and that we can take it from there and really can take to market even better than we have done in the past. Thank you for that. Thank you.

[END OF TRANSCRIPT]

GLOBAL TOWN HALL


FFF

A New Global Innovative Integrated Solutions Leader

AGENDA

- 1) IFF & DuPont N&B Introduction
- 2) Strategic Rationale of Combination
- 3) Integration Update
- 4) Conclusion

iff



IFF'S TRANSFORMATIONAL JOURNEY

Achieving our vision by building on our legacy to redefine our future

	2015	2019E	2021E+	
	iff		IFF + ^{DuPont} Nutrition & Biosciences	
Sales Evolution	~\$3B	\$5B		
Employees	6,700	13,000	23,000	
R&D Spend	~\$250M	~\$350M	>\$550M	
# of Granted Patents	~1,300	~1,600	~9,000	
Differentiated Solutions	Specialized provider	Technical bundle	Integrated Solutions	
Customers	~3,000	~39,000	>40,000	
Positioning & Capabilities	#4 Taste & Scent	#2 Taste & Scent	#1 & #2 Taste, Scent, Nutrition, Cultures, Enzymes, Probiotics, Soy Proteins	
4			iff	

SNAPSHOT OF DUPONT N&B


Innovation-driven portfolio of high-value, specialty ingredient businesses



5 (1) Operating EBITDA is on a pro forma basis and is defined as earnings (i.e. income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, nonoperating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding the impact of costs historically allocated to the materials science and agriculture businesses that did not meet the criteria to be recorded as discontinued operations and excluding significant items.

COMPELLING COMBINATION


Complementary portfolios that build on the best of both capabilities & talent





TECHNOLOGY & INNOVATION

Expanded capabilities through R&D and innovation platforms





LEADER ACROSS ATTRACTIVE MARKETS

Breadth of capability & exposure establishes strong competitive position

	tegory Leader Position rticipates in the category	IFF + DuPont N&B	Peer 1	Peer 2	Peer 3	Peer 4	Peer 5	Peer 6
Food & Beverage	Functional Solutions ⁽¹⁾	Ğ	\checkmark	\checkmark				
	Emulsifiers & Lecithin	Ğ		\checkmark				
	Sweeteners ⁽²⁾	8	\checkmark					
	Plant Protein (2)	Ğ		\checkmark				
Health & Bioscience	Cultures	ĕ	\checkmark					8
	Probiotics	ĕ		\checkmark		\checkmark		8
	Enzymes	ĕ	\checkmark	\checkmark			8	\checkmark
	Animal Nutrition ⁽¹⁾	\checkmark	\checkmark				\checkmark	\checkmark
Pharma	Excipients	ĕ		\checkmark				
	Nutraceuticals ⁽¹⁾	\checkmark	\checkmark		\checkmark	\checkmark		
Flavor & Fragrance	Flavors	8		\checkmark	8	\checkmark		
	Fragrances	ĕ			8	\checkmark		
	Cosmetic Ingredients ⁽¹⁾	\checkmark	\checkmark		\checkmark	\checkmark		

Evolving Customer Demand For More Integrated Solutions

8 Source: Company Information 1. Functional solutions, Animal Nutrition, Nutraceuticals and Cosmetic Ingredients are widely defined categories with limited traditional "leadership" 2. In relevant segments iff

HIGHLY COMPELLING POSITION WITH CUSTOMERS

Clear path to become a partner of choice





DIFFERENTIATED SOLUTIONS

Complementary capabilities and expertise in Food & Beverage

Demand Across Shared End-Markets		Illustrative Product Examples			
	Food & Beverage	 IFF Product Offering DuPont N&B Product Offering 			
	Health & Wellness	Better Plant-Based Based System Blends (Dairy-free cheese) Flavor & Seasonings (Taste)			
	Home & Personal Care	Burger Taste Modulation (Bitterness & salt reduction) Delivery Systems (Flavor performance) Natural Antioxidants (Food protection) Natural Color & Grill Mark (For appearance & clean label)			
	speed to market with nced outcomes	iff			



DIFFERENTIATED SOLUTIONS

Complementary capabilities and expertise in Fabric, Home & Personal Care



APPROACH FOR N&B INTEGRATION

Deal close targeted for Q1 2021

- IFF and N&B are highly complementary companies
- We see value in our unique skills working together
- Rich O'Leary (IFF) and Angela Naef (DuPont) appointed integration leaders
- Integration Management Office (IMO) established including members of IFF and N&B
- Leverage learning & best practice of previous deals by both companies
- Creating a culture of creativity, science, innovation, sustainability & execution

We Will Keep You Informed Along The Way

12 (1) Separation Committee still to be announced

Creating a global value-added ingredients & solutions provider

- Proven leader and trusted partner with our own customers
- Deep focus on consumer-driven end markets
- Passionate commitment to a science-led, innovation-first culture
- Complementary capabilities & product portfolio with limited overlap

iff

Dedication to sustainable practices, development and safety



About IFF

At IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), we're using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at <u>iff.com</u>, <u>Twitter</u>, <u>Facebook</u>, <u>Instagram</u>, and <u>LinkedIn</u>.

About DuPon

DuPont (NYSE:DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at <u>www.dupont.com</u>.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: www.dupontnutritionandhealth.com or www.biosciences.dupont.com.

Additional Information and Where to Find It

This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote of approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the "Securities Act"). In connection with the proposed combination of Nutrition & Biosciences, Inc. ("N&Bco"), a wholly owned subsidiary of DuPont de Nemours, Inc. ("DuPont"), and International Flavors & Fragrances Inc. ("IFF"), which will immediately follow the proposed separation of N&Bco from DuPont (the "proposed transaction"), N&Bco and IFF intend to file relevant materials with the SEC, including a registration statement on Form S-4 that will include a proxy statement/prospectus relating to the proposed transaction. In addition, N&Bco expects to file a registration statement in connection with its separation from DuPont. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENTS, PROXY STATEMENT/PROSPECTUS AND DAVY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT IFF, N&BCO AND THE PROPOSED TRANSACTION. A definitive proxy statement will be sent to shareholders of IFF seeking approval of the proposed transaction. The documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC's website at <u>www.sec.gov</u>. Free copies of these documents, once available, and each of the companies' other filings with the SEC may also be obtained from the respective companies by contacting the investor relations department of DuPont or IFF at the following:

Media:

Dan Turner

+1 302-996-8372

Daniel.a.turner@dupont.com

IFF Contact Information Michael DeVeau Michael.DeVeau@iff.com +1 212-708-7164

DuPont Contact Information DuPont Investors: Lori Koch Lori.d.koch@dupont.com +1 302-999-5631



CAUTIONARY STATEMENT

This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In this context, forward-looking statements of then address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan, "believe," "seek," "see," "will," "would," target," similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the proposed transaction, the expected timetable for completing the proposed transaction, target velos, future experts, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and target business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. There are several factors which could cause actual plans and results to differ materially from those expressed or implied in forward-looking statements. Such factors include, but are not limited to, (1) the presis ability to meet expectations regarding undificited to complete the separation on any capacitary to the other conditions to the proposed transaction, (2) changes in relevant tax and other laws, (3) and costs and pursuit and/or implementation of the separation on any capacitary the econfiguration of businesses included in the separation in any stars related as in domardical condition changes and pursuit and/or implementation of Dev Inco. A print 1, 2019 and/or the Corteva Distributions", (1) the relaxed standerds, or on and other performance, indebtedness, financial condition, as result to a dress of assets and businesses, (1) potential liability arising from fraudulet conveyance and other proficio changes, inc (13) the failure to achieve expected or targeted future financial and operating performance and results, (14) the possibility that IFF may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected following the proposed transaction, (16) the impossed transaction as well as other conditional commitments, (17) episability that IFF may be unable to achieve expected following the proposed transaction, (16) the impossed transaction takes (including et or any contrast or containing on the effective expected following the proposed transaction, (16) the impossed transaction as well as other conditional commitments, (17) episability effects of the announcement or the consumation of the transaction and uncertainty as to the long-term value of IFFs common stock, (22) risks related to IFFs or common stock, (22) risks re iff

PARTICIPANTS IN THE SOLICITATION

This communication is not a solicitation of a proxy from any investor or security holder. However, DuPont, IFF and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction under the rules of the SEC. Information about the directors and executive officers of DuPont may be found in its Annual Report on Form 10-K filed with the SEC on February 11, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019. Information about the directors and executive officers proxy statement filed with the SEC on May 1, 2019. Information about the directors and executive officers or proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on May 1, 2019 and its definitive proxy statement filed with the SEC on

iff